Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trying for a BRAF Slam Dunk.

Cancer discovery - 1 May 2020

Ribas Antoni, Lo Roger S

Abstract excerpt

The first basket clinical trial testing the BRAF inhibitor vemurafenib resulted in evidence of activity in 13 unique cancer types with BRAF V600 mutations, but the response rates were variable. Therefore, different cancer histologies with the same driver oncogene display different degrees of oncogenic pathway addiction.See related article by Subbiah et al., p. 657.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Neoplasms
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 32357967
DOI: 10.1158/2159-8290.CD-20-0231
PMCID: PMC7363198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trying for a BRAF Slam Dunk.PMID 32357967Read ↗

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.Semantic proximity Read ↗

Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.Semantic proximity Read ↗

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma CancersSemantic proximity Read ↗

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.Semantic proximity Read ↗

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022Semantic proximity Read ↗

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.Semantic proximity Read ↗

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsSemantic proximity Read ↗

Bespoke treatment: drivers beware!Semantic proximity Read ↗

A new BRAF inhibitor breaks resistance barriers.Semantic proximity Read ↗

Targeting KRAS: Good, But Is It Good Enough?Semantic proximity Read ↗

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.Semantic proximity Read ↗

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.